Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chronic total occlusion (CTO) refers to a complete blockage (100% occlusion) of a coronary artery persisting for three months or longer, usually caused by atherosclerotic plaque formation. CTO is a severe manifestation of coronary artery disease and commonly results in symptoms of angina, shortness of breath, and increased risk for myocardial infarction. Treatments focus on restoring blood flow, often through percutaneous coronary intervention (PCI) with stenting or coronary artery bypass grafting (CABG). CTO is assessed by angiography and is not a protein, gene, or molecular receptor but a clinical syndrome caused by physical obstruction in a blood vessel.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chronic total occlusion of the coronary artery (CTO).